Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)
The current prophylactic treatment to prevent rheumatic heart disease requires four-weekly intramuscular injection of a suspension of the poorly soluble benzathine salt form of penicillin G (BPG) often for more than 10 years. In seeking to reduce the frequency of administration to improve adherence, biodegradable polymer matrices have been investigated. Poly(lactide-co-glycolide) (PLGA)-based in situ forming precursor systems containing N-methyl-2-pyrrolidone as solvent and PLGA-based monolithic implants for surgical implantation containing BPG were developed. Long-term release studies indicated low and plateaued release of penicillin G, but continual favourable release profiles for the benzathine counterion, indicating degradation of the polymer and generation of acidic microenvironment being detrimental to penicillin stability. In order to avoid the issue of the acidic product, poly(caprolactone)(PCL) implants were also investigated, with favourable penicillin G release behaviour being achieved, and slow release over 180 days. However, when taking into account the mass of polymer, and the total dose of drug calculated from literature pharmacokinetic parameters for penicillin G, we concluded that an implant size of over 7 g would still be required. This may preclude clinical deployment of a polymer matrix type delivery system for this indication in children and adolescents. Therefore, we have learned that biodegradable PLGA-type systems are not suitable for development of sustained release BPG treatments and that although the PCL system provides favourable release behaviour, the total size of the implant may still present a hurdle for future development.
KeywordsRheumatic fever Antibiotic Sustained release Drug delivery PLGA Therapeutic implant
The authors wish to thank Charlotte Mulder, Errol Malta and Mark Sullivan from Medicines Development Ltd. (MDL) for their helpful discussions on this work. The authors would also like to thank Corbion Purac for providing samples of PLA/PLGA copolymers free of charge.
Jonathan Carapetis and Ben Boyd have received funding from the Telethon New Children’s Hospital Research Fund to explore new formulations of benzathine penicillin G (Grant number: F55541).
Compliance with ethical standards
Conflict of interest
Jonathan Carapetis and Meru Sheel are investigators on a BPG projected funded by Novartis Institutes for BioMedical Research. Rosemary Wyber has provided technical advice to Pfizer on BPG but has not received funding.
- 7.Currie B. Benzathine penicillin—down but not out. North Territ Dis Control Bull. 2006;13(2):1–3.Google Scholar
- 8.Holanda e Silva K, et al. New insight about pharmaceutical dosage forms for benzathine penicillin G. Rev Ciênc Farm Básica Apl. 2006;27(1):21–6.Google Scholar
- 9.Broderick MP, Hansen CJ, Russell KL, Kaplan EL, Blumer JL, Faix DJ. Serum penicillin G levels are lower than expected in adults within two weeks of administration of 1.2 million units. PLoS One. 2011;6(10):e25308. https://doi.org/10.1371/journal.pone.0025308.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Wyber R, Boyd BJ, Colquhoun S, Currie BJ, Engel M, Kado J, et al. Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Deliv Transl Res. 2016;6(5):572–8. https://doi.org/10.1007/s13346-016-0313-z.CrossRefPubMedGoogle Scholar
- 12.Ikada Y, Tsuji H. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun. 2000;21(3):117–32. https://doi.org/10.1002/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.0.CO;2-X.CrossRefGoogle Scholar
- 18.Malik K, et al. Atrigel: a potential parenteral controlled drug delivery system. Der Pharmacia Sinica. 2010;1(1):74–81.Google Scholar
- 19.Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27(9):1735–40. https://doi.org/10.1016/j.biomaterials.2005.09.019.CrossRefPubMedGoogle Scholar
- 20.Dunn RL. The Atrigel drug delivery system. In: Drugs and the pharmaceutical sciences. New York: Dekker; 2003. p. 647–55.Google Scholar
- 21.Patel DB. A review on atrigel drug delivery system. J Glob Pharma Technol. 2010;2:85–90.Google Scholar
- 22.Eligard® Full prescribing information sheet. Tolmar Pharmaceuticals. 04/08/2014]; http://www.eligard.com/Docs/Pdf/TOLMAR%20Pharmaceuticals_Web_PI_05-07-14.pdf].
- 23.Atridox® Full prescribing information sheet. Tolmar Pharmaceuticals. 04/08/2014]; http://www.carepathways.com/DictionaryFDA2.cfm?RetDoc=http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050751s015lbl.pdf&drugname=ATRIDOX&ActiveIngredient=DOXYCYCLINEHYCLATE&type=Label].
- 29.Wischke C, Schwendeman SP. Degradable polymeric carriers for parenteral controlled drug delivery. In: Siepmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Boston: Springer US; 2012. p. 171–228. https://doi.org/10.1007/978-1-4614-0881-9_8.CrossRefGoogle Scholar